Mark Gardner
Impact in
- Pharmacology top 2%
- Pharmacogenetics and Drug Metabolism
- Antibiotics Pharmacokinetics and Efficacy
- Psychiatry and Mental health top 5%
- Attention Deficit Hyperactivity Disorder
Papers in
- Co-authors
- Jerome J. Schentag (4 shared papers)William J. Jusko (5 shared papers)Donald M. Hilligoss (5 shared papers)Mark D. Rapport (2 shared papers)George J. DuPaul (2 shared papers)Colin B. Denney (1 shared paper)Antoinette Mangione (2 shared papers)John W. Vance (1 shared paper)
- Journals
- Journal of Clinical Oncology (6 papers)The Journal of Clinical Pharmacology (5 papers)Clinical Pharmacology & Therapeutics (4 papers)Journal of Pharmaceutical Sciences (2 papers)Oncotarget (2 papers)
- Partner nations
- United StatesFrance
In The Last Decade
Mark Gardner
37 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 112
- Pharmacology 257
- Psychiatry and Mental health 275
- Pharmacology 234
- Infectious Diseases 236
- Transplantation 34
Countries citing papers authored by Mark Gardner
This map shows the geographic impact of Mark Gardner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Gardner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Gardner more than expected).
Fields of papers citing papers by Mark Gardner
This network shows the impact of papers produced by Mark Gardner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Gardner. The network helps show where Mark Gardner may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Gardner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1979 | 201 | |
| 2 | 1994 | 167 | |
| 3 | 1991 | 134 | |
| 4 | 1978 | 130 | |
| 5 | 1991 | 95 | |
| 6 | 1991 | 91 | |
| 7 | 1987 | 84 | |
| 8 | 2017 | 56 | |
| 9 | 1991 | 51 | |
| 10 | 2014 | 49 | |
| 11 | 1993 | 44 | |
| 12 | 1995 | 38 | |
| 13 | 2016 | 33 | |
| 14 | 1988 | 26 | |
| 15 | 1997 | 25 | |
| 16 | 2006 | 21 | |
| 17 | 2006 | 17 | |
| 18 | 1983 | 15 | |
| 19 | 2018 | 14 | |
| 20 | 2019 | 14 |
About Mark Gardner
Mark Gardner is a scholar working on Oncology, Genetics, Pharmacology, Pharmacology and Endocrinology, Diabetes and Metabolism, having authored 39 papers that have together received 1.4k indexed citations. Recurring topics across this work include Estrogen and related hormone effects (9 papers), Cancer Immunotherapy and Biomarkers (8 papers), Pharmacogenetics and Drug Metabolism (7 papers), Cancer Genomics and Diagnostics (6 papers), Menopause: Health Impacts and Treatments (4 papers), Hormonal Regulation and Hypertension (4 papers), Antifungal resistance and susceptibility (3 papers) and Immunotherapy and Immune Responses (3 papers). The work is most often cited by research in Pharmacology (257 citations), Psychiatry and Mental health (275 citations), Pharmacology (234 citations), Infectious Diseases (236 citations) and Transplantation (34 citations). Mark Gardner has collaborated with scholars based in United States and France. Frequent co-authors include Jerome J. Schentag, William J. Jusko, Donald M. Hilligoss, Mark D. Rapport, George J. DuPaul, Colin B. Denney, Antoinette Mangione, John W. Vance, Jeffrey R. Koup and Robert A. Blum. Their work appears in journals such as Journal of Clinical Oncology, The Journal of Clinical Pharmacology, Clinical Pharmacology & Therapeutics, Journal of Pharmaceutical Sciences and Oncotarget.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.